PRINCETON, N.J.--(BUSINESS WIRE)--PharmaNet Development Group, Inc. (NASDAQ: PDGI), a leading provider of drug development services to branded pharmaceutical, biotechnology, generic drug and medical device companies, today reported GAAP net earnings from continuing operations for its third quarter ended September 30, 2006 of $3.0 million or $0.16 per diluted share.
